ApconiX Press Category archive

Improve Drug Project Success by Understanding Drug Target Safety

Improve Drug Project Success by Understanding Drug Target Safety Join Professor Ruth Roberts, Director and Co-founder, ApconiX Ltd, Dr Claire Sadler, Project Toxicologist, ApconiX and Dr Leigh Ann Burns Nass, President/Owner, Magnolia Toxicology Consulting, LLC in a live webinar on Thursday, October 1, 2020 at 11am EDT (4pm BST/UK) In [...]

By |2022-09-21T14:19:36+01:00September 24th, 2020|Press|Comments Off on Improve Drug Project Success by Understanding Drug Target Safety

Dr Guy Healing Appointed Honorary Professor

Dr Guy Healing Appointed Honorary Professor ApconiX is pleased to announce that Dr Guy Healing has been appointed to an Honorary Professorship in the School of Pharmacy at the University of East Anglia (UEA), Norwich, UK. Guy first became involved with the UEA when he worked for AstraZeneca.  One [...]

By |2022-09-21T14:10:37+01:00May 20th, 2020|Press|Comments Off on Dr Guy Healing Appointed Honorary Professor

How Alderley Park Grew into an Innovation Hub

How Alderley Park Grew into an Innovation Hub A great piece in the Financial Times this week “How Alderley Park Grew into an Innovation Hub” which highlights the success of Alderley Park following AstraZeneca’s announced departure 5 years ago.  Ned Wakeman talks about his team’s continued support of the start-up companies [...]

By |2021-08-13T13:43:47+01:00July 31st, 2019|Press|Comments Off on How Alderley Park Grew into an Innovation Hub

ApconiX Welcomes Ian Slater to the Team

ApconiX Welcomes Ian Slater to the Team ApconiX is delighted to welcome Ian Slater to the team.  Ian has spent many years in the pharmaceutical industry as a toxicology Study Director and Study Monitor and he joins our nonclinical study monitoring team.  Ian was previously an Associate Principal Toxicologist [...]

By |2022-02-22T13:02:39+00:00April 30th, 2019|Press|Comments Off on ApconiX Welcomes Ian Slater to the Team

Cost Effective Study Monitoring Services at Non-Clinical CROs in North America

Cost Effective Study Monitoring Services at Non-Clinical CROs in North America Steve Snyder is partnering with ApconiX to provide cost-effective study monitoring services at nonclinical CROs in North America.  Steve is a US-based independent consultant who currently provides study monitoring services for clients ranging from global pharmaceutical companies to [...]

By |2022-12-13T17:45:51+00:00February 20th, 2019|Press|Comments Off on Cost Effective Study Monitoring Services at Non-Clinical CROs in North America

Study Monitoring – Why Is It Important?

Study monitoring – What is it and why is it important to drug discovery projects? Guy Healing, Senior Toxicologist at ApconiX is interviewed by Jon Clements of Metamorphic PR Pharma companies need to ensure their drugs are safe but also that they work. In drug development, this requires numerous studies to [...]

By |2022-10-19T15:41:58+01:00February 6th, 2019|Press|Comments Off on Study Monitoring – Why Is It Important?

ApconiX Welcomes Steve Snyder

ApconiX Welcomes Steve Snyder ApconiX is delighted to welcome Steve Snyder to the team.  Steve joins the nonclinical study monitoring team and is based in Florida in the United States. Having worked at Wyeth, Eli Lilly, McNeil Pharmaceutical and Charles River, Steve has a wealth of experience in preclinical [...]

By |2022-12-13T17:56:29+00:00February 6th, 2019|Press|Comments Off on ApconiX Welcomes Steve Snyder

Choosing the right non-clinical CRO

Choosing the right non-clinical CRO Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical [...]

By |2024-01-23T10:53:49+00:00September 19th, 2018|Press, Toxicology|Comments Off on Choosing the right non-clinical CRO

Safety Must Be Prioritized In Drugs for Cancer

Despite the fact that the number of diagnosed cases of malignant mesothelioma are expected to rise in the next decades, there has been little real progress in available treatments, and the chemotherapy drug used to treat the disease is the same one that has been used for the last several  years. Though there is a [...]

By |2018-07-11T10:00:27+01:00May 16th, 2018|Press|Comments Off on Safety Must Be Prioritized In Drugs for Cancer

Attitude Toward Safety in Needs to Change

A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change. “There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety issues [...]

By |2018-06-27T16:32:28+01:00February 20th, 2018|Press|Comments Off on Attitude Toward Safety in Needs to Change
Go to Top